Medicox메디콕스
054180 · KOSDAQ · ₩054180 · 메디콕스
₩2,295 ₩0 (0.00%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩6.4B | ₩6.3B | ₩7B | ₩6.7B | ₩7.7B | ₩6.8B | ₩8.2B | ₩7.6B |
| Cost of sales | ₩6.2B | ₩5.8B | ₩7B | ₩5.8B | ₩6.9B | ₩6.2B | ₩7.6B | ₩7.1B |
| Gross profit | ₩249M | ₩553M | −₩18M | ₩840M | ₩761M | ₩584M | ₩541M | ₩499M |
| Operating income | −₩1.1B | −₩1B | −₩1.3B | −₩923M | −₩1.5B | −₩2B | −₩2.1B | −₩2.2B |
| Net income | ₩498M | −₩1.6B | −₩10B | ₩1.8B | −₩842M | −₩2.9B | −₩18B | ₩3.6B |
| Net income to shareholders | ₩498M | −₩1.6B | −₩10B | ₩1.8B | −₩842M | −₩2.9B | −₩7.3B | −₩3.8B |
Balance sheet
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total assets | ₩69B | ₩69B | ₩68B | ₩72B | ₩77B | ₩84B | ₩81B | ₩79B |
| Current assets | ₩8.3B | ₩8.9B | ₩7.5B | ₩9.4B | ₩12B | ₩16B | ₩13B | ₩17B |
| Cash and equivalents | ₩40M | ₩36M | ₩377M | ₩585M | ₩589M | ₩4.6B | ₩1.2B | ₩436M |
| Total liabilities | ₩24B | ₩24B | ₩21B | ₩22B | ₩25B | ₩27B | ₩29B | ₩28B |
| Current liabilities | ₩19B | ₩19B | ₩16B | ₩16B | ₩19B | ₩22B | ₩24B | ₩24B |
| Borrowings | ₩8.5B | ₩8.5B | ₩8.5B | ₩8.7B | ₩11B | ₩16B | ₩18B | ₩19B |
| Total equity | ₩45B | ₩46B | ₩47B | ₩51B | ₩52B | ₩56B | ₩52B | ₩51B |
| Shareholders' equity | ₩45B | ₩46B | ₩47B | ₩51B | ₩52B | ₩56B | ₩52B | ₩51B |
Cash flow
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | ₩836M | −₩112M | −₩79M | −₩810M | −₩286M | −₩2.3B | −₩530M | −₩1.6B |
| Capital spending | ₩242M | ₩61M | ₩40M | ₩211M | ₩503M | ₩21M | ₩90M | ₩119M |
| Free cash flow | ₩594M | −₩173M | −₩118M | −₩1B | −₩789M | −₩2.3B | −₩620M | −₩1.7B |
Consolidated where available. Amounts in won.
Also known as: Medicox / 메디콕스 / 054180 / KRX:054180
Source: KRX statistical information